Histologic findings associated with laser interstitial thermotherapy for glioblastoma multiforme.

BACKGROUND: Laser-interstitial thermal therapy (LITT) has been supported by some authors as an ablative treatment of glioblastoma multiforme (GBM). Although the effects of LITT have been modeled in vivo, the histologic effects in a clinical circumstance have not been described. We analyzed tissue from a patient who underwent LITT as primary treatment for GBM. CASE PRESENTATION: A 62-year-old male was diagnosed with a left temporal GBM and underwent LITT at an outside institution. Despite corticosteroid therapy, the patient was referred with increasing headache and acalculia associated with progressive peritumoral edema two weeks after LITT procedure. En bloc resection of the enhancing lesion and adjacent temporal lobe was performed with steroid-independent symptom resolution (follow-up, > 2 years). Histologic analysis revealed three distinct histologic zones concentrically radiating from the center of the treatment site. An acellular central region of necrosis (Zone 1) was surrounded by a rim of granulation tissue with macrophages (CD68) (Zone 2; mean thickness, 1.3 ± 0.3 mm [±S.D.]). Viable tumor cells (identified by Ki-67, p53 and Olig2 immunohistochemistry) were found (Zone 3) immediately adjacent to granulation tissue. The histologic volume of thermal tissue ablation/granulation was consistent with preoperative (pre-resection) magnetic resonance (MR)-imaging. CONCLUSION: These findings are the first in vivo in humans to reveal that LITT causes a defined pattern of tissue necrosis, concentric destruction of tumor and tissue with viable tumor cells just beyond the zones of central necrosis and granulation. Furthermore, MR-imaging appears to be an accurate surrogate of tissue/tumor ablation in the early period (2 weeks) post-LITT treatment. Surgery is an effective strategy for patients with post-LITT swelling which does not respond to steroids.

Comparative Utility of Dynamic and Static Imaging in the Management of Lumbar Spondylolisthesis.

OBJECTIVE: Segmental instability traditionally is investigated with flexion and extension (F/E) radiographs. We sought to determine whether motion between upright and supine (U/S) views can serve as an alternative sensitive diagnostic tool that predicts similar outcomes. METHODS: Ambispective collection of data was performed for 222 consecutive patients who underwent transforaminal lumbar interbody fusion. Patients were divided into either group 1 (≥3 mm spondylolisthesis difference between F/E radiographs) or group 2 (≥3 mm spondylolisthesis difference between U/S imaging and otherwise not meeting group 1 criteria). RESULTS: In total, 77 patients met all inclusion/exclusion criteria. Patients in group 1 (n = 26) and group 2 (n = 51) did not differ with respect to key demographic criteria. Average clinical follow-up for groups 1 and 2 were 31.8 and 35.6 months (P = 0.43). Average spondylolisthesis was 8.1 mm and 8.0 mm for groups 1 and 2 (P = 0.93). The incidence of facet joint hyperintensity on T2-weighted magnetic resonance imaging and average maximal facet joint widening (P > 0.2) did not differ between groups. Average F/E slip change was 5.0 mm for group 1 and average U/S slip change was 5.2 mm for group 2. For both groups, Numeric Rating Scale Back Pain and Numeric Rating Scale Leg Pain, Oswestry Disability Index v2.1a, and Short-Form 36 RAND (P < 0.02) improved significantly after surgery. Furthermore, ΔNumeric Rating Scale Back Pain, ΔNumeric Rating Scale Leg Pain, ΔOswestry Disability Index v2.1a, and ΔShort-Form 36 RAND (P > 0.2) were not significantly different between groups. CONCLUSIONS: No differences in outcomes were noted between patients based on either imaging criteria. These data suggest that static U/S imaging may identify a distinct group of patients who may benefit from transforaminal lumbar interbody fusion surgery.

A national survey of spinal cord stimulation trial-to-permanent conversion rates.

OBJECTIVES: Conversion rates from trial leads to permanent spinal cord stimulation (SCS) systems have recently come under scrutiny. Our goal was to examine the rate of conversion from trial lead to permanent system placement as well as identify factors associated with successful SCS conversion. MATERIALS AND METHODS: We designed a large retrospective analysis using the Thomson Reuters MarketScan database. We included all patients who underwent a percutaneous trial of neurostimulatory electrodes from the years 2000 to 2009 who were aged 18 and older. Patients were then tracked to see if they went on to receive a permanent SCS system. Patients were also analyzed in univariate and multivariate models to identify factors associated with successful conversion. RESULTS: A total of 21,672 unique instances of percutaneous trials were identified. Overall, 41.4% of those receiving trials went on to have a permanent SCS system installed within the subsequent three months. Factors associated with increased likelihood of successful conversion included having commercial insurance (43% vs. 37%, p < 0.0001), younger age (43% for those aged 35-44 vs. 39% for those aged 65 and older, p < 0.0001), and never having had a previous percutaneous trial attempt (44% for first-time trials vs. 27% for those on their second trial vs. 14% for those on their third or later trial, p < 0.0001). In multivariate analysis, we found significant variation in conversion rate by geographic area (patients in the North Central region vs. Northeast region: odds ratio 1.48, 95% confidence interval [1.31, 1.66]; p < 0.0001). CONCLUSIONS: In this study of a national cohort of patients, we identified specific factors associated with higher conversion rates, along with significant geographical variation. In general, there is a need for better patient selection by physicians who practice neuromodulation.